The human ribonucleoprotein ribonuclease P (RNase P), processing tRNA, has at least 10 distinct protein subunits. Many of these subunits, including the autoimmune antigen Rpp38, are shared by RNase MRP, a ribonucleoprotein enzyme required for processing of rRNA. We here show that constitutive expression of exogenous, tagged Rpp38 protein in HeLa cells affects processing of tRNA precursors. Alterations in the site-speci®c cleavage and in the steady-state level of 3¢ sequences of the internal transcribed spacer 1 of rRNA are also observed. These processing defects are accompanied by selective shut-off of expression of Rpp38 and by low expression of the tagged protein. RNase P puri®ed from these cells exhibits impaired activity in vitro. Moreover, inhibition of Rpp38 by the use of small interfering RNA causes accumulation of the initiator methionine tRNA precursor. Expression of other protein components, but not of the H1 RNA subunit, is coordinately inhibited. Our results reveal that normal expression of Rpp38 is required for the biosynthesis of intact RNase P and for the normal processing of stable RNA in human cells.
INTRODUCTION
Biochemical puri®cation of the human tRNA processing enzyme ribonuclease P (RNase P) has revealed that this ribonucleoprotein possesses at least 10 distinct protein subunits, associated with one RNA species, H1 RNA (1,2). These protein subunits are designated Rpp14, Rpp20, Rpp21, Rpp25, Rpp29, Rpp30, Rpp38, Rpp40, hPop5 and hPop1 (3± 9). Some of these protein subunits have homologs in yeast (10±15) and archaea (16) .
The subunit composition of nuclear RNase P is shared, in part, with the ribonucleoprotein RNase MRP, processing rRNA (17, 18) . In yeast, RNase MRP is required for mitochondrial DNA replication (19) , for processing of the internal transcribed spacer 1 (ITS1) of rRNA (17, 20, 21) and for the cell cycle progression at the end of mitosis (17, 22) . The involvement of these two ribonucleoprotein enzymes in stable RNA processing or in the cell cycle, however, has not been demonstrated in human cells. One of the subunits shared by RNase P and RNase MRP is Rpp38, a protein with a major Th/To autoantigenic determinant (23) . Rpp38 has sequence similarity with the Haloarcula marismortui L7Ae and it may bind the K-turn structure in the RNA component of RNase MRP (24) . Rpp38 is primarily localized in the nucleolus and Cajal bodies of mammalian cells and appears to have a role in coordinating the intranuclear localization and assembly of RNase P and RNase MRP (25, 26) . Recent ®ndings suggest that Pop3, the yeast homolog of Rpp38, is dispensable for tRNA substrate recognition and catalysis by nuclear RNase P (27) .
We show here that constitutive expression in HeLa cells of an exogenous Rpp38 protein causes shut-off in expression of the endogenous Rpp38 and affects the biosynthesis of an intact RNase P. A decrease in the processing of the initiator methionine precursor tRNA, as well as miscleavage and rapid degradation of the 3¢ sequences of ITS1 rRNA, are observed. Moreover, by using small interfering RNA (siRNA) directed against Rpp38 mRNA, we demonstrate that inhibition of expression of Rpp38 affects processing of precursors for tRNA and 5.8S rRNA. The results presented in this study reveal that normal expression of a single protein subunit of RNase P affects its structure and function in human cells.
MATERIALS AND METHODS

Cell culture and transfection
Stable transfection of HeLa S3 cells was performed using the calcium phosphate method and individual cell lines obtained were maintained in a selective medium that contained 0.4 mg/ml G418. For transfection of cells with synthetic siRNA (Dharmacon Research Inc., Lafayette CO) directed against Rpp38, Oligofectamine reagent was used, following the instructions of the manufacturer (Invitrogen). When siRNA and plasmids were introduced simultaneously into cells, Lipofectamine plus (Invitrogen) was utilized.
Gene constructs and probes
Two primers, one encompassing the ®rst 22 nt of the 5¢-untranslated region (5¢-UTR) of Rpp38 and the other containing the last 29 nt of the Rpp38 open reading frame *To whom correspondence should be addressed. Tel: +972 2 6758233; Fax: +972 2 6784010; Email: jarrous@md.huji.ac.il
The authors wish it to be known that, in their opinion, the ®rst two authors should be regarded as joint First Authors and an extra 18 nt that correspond to six histidine residues followed by a stop codon, were used to amplify Rpp38 cDNA (4) . This cDNA was ®rst subcloned into pBluescript, sequenced and then the cDNA was released by EcoRI and XbaI (located in the 3¢ primer) and inserted into a pCI-neo vector (Promega) digested with EcoRI and XbaI, thereby generating pCIRpp38H.
For RNase protection analysis, probe B (Fig. 1C ) was prepared by linearizing pCIRpp38H with NcoI located in the Rpp38 C-terminus (4) and transcribed using the T3 RNA polymerase promoter located downstream of the Rpp38H cDNA. Probe A (Fig. 1C) was generated by transcribing with T7 RNA polymerase a HindIII±PstI Rpp38 cDNA fragment subcloned in pBluescript. This fragment contains the 5¢-UTR and the ®rst 9 nt of the Rpp38 open reading frame.
pTZ18R/ITS1 and pTZ18R/ITS2 were kindly provided by Jean-Pierre Bachellerie (CNRS, Toulouse, France). A 568 bp NarI±KpnI fragment of human genomic rDNA, encompassing positions 31±598 of the 1095 bp ITS1, was subcloned in pTZ18R digested by AccI and KpnI. This plasmid was linearized by cleavage at the HindIII site located in the multiple cloning site of the plasmid and transcribed by T7 RNA polymerase to yield an antisense RNA complementary to 568 nt of the 5¢ region of ITS1 RNA. A 937 bp MluI±HinfI segment of human genomic rDNA, covering positions 176± 1112 of the 1155 bp ITS2, was inserted into pTZ18R that was digested with SmaI. pTZ18R/ITS2 was linearized with NotI located within the ITS2 rDNA segment and transcribed by T7 RNA polymerase to yield an antisense RNA covering positions 855±1112. A pT3/T7a19 plasmid that harbors an EcoRI±HindIII PCR product that covers positions 606±1094 of the human ITS1 rDNA was kindly provided by David Tollervey (University of Edinburgh, Edinburgh, UK). The construct was linearized with EcoRI and the insert was transcribed by T7 RNA polymerase to yield a 488 nt antisense probe.
The human tRNA i Met gene (clone T54T60) subcloned in pT3/T7a, kindly provided by Uttam L. RajBhandary (MIT, Cambridge, MA), was linearized with EcoRI and an antisense RNA probe was synthesized using T3 RNA polymerase, while a clone for the human tRNA Ser gene was transcribed by T7 RNA polymerase.
Antisense oligonucleotides 5¢-TCCTGCAATTCACATT-AATTCTCGCAGCTAGC-3¢, 5¢-AAAGCCTACAGCACCC-GGTATTCCC-3¢ and 5¢-TCCTCCGAGCCGGATTCGAA-3¢ directed against human 5.8S rRNA, 5S rRNA and tRNA Tyr GUA respectively, were 5¢ end labeled by T4 polynucleotide kinase using [g-32 P]ATP.
A custom-designed siRNA, which corresponds to positions 158±180 (5¢-AAGCUAUUGGACUUCAGAAGAUU-3¢) of the open reading frame of Rpp38 mRNA (4) was used for targeting Rpp38 in cells. The complementary synthetic strands of siRNA38 used in this study were as follows: 5¢-GCUAUUGGACUUCAGAAGAUUdTdT-3¢ and 3¢-dTdTCGA-UAACCUGAAGUCUUCUAA-5¢.
RNA hybridization analyses
Total RNA was extracted from 0.5±1 Q 10 7 cells with the use of Trizol reagent (Invitrogen) or by the acid/phenol RNA extraction method. RNA (30 mg) was subjected to RNase protection analysis using 0.5 Q 10 6 c.p.m. of antisense RNA probe internally labeled with [a-32 P]GTP in the presence of cold GTP. For rRNA analysis, 2±5 mg of total RNA was analyzed. Hybridization was performed in 40 ml of buffer A (80% deionized formamide, 40 mM PIPES, pH 6.7, 400 mM NaCl and 1 mM EDTA) for 14 h at 42±46°C. RNA was digested for 15 min at 22±25°C by adding 10 vol of buffer B (10 mM Tris±HCl, pH 7.5, 5 mM EDTA, 300 mM NaCl) that contained 0.8 mg/ml RNase A and 60 U/ml RNase T1. RNases were then eliminated by proteinase K/SDS treatment and the protected RNA was extracted with phenol:chloroform and ethanol precipitated in the presence of tRNA as a carrier. The pellet of RNA was resuspended in loading buffer (95% formamide, 10 mM Tris±HCl, pH 7.5, 1 mM EDTA), heat denatured and separated on a 4±6% polyacrylamide/7 M urea gel. For single-stranded DNA size markers, pBluescript DNA was digested with MspI and labeled with [a-32 P]dCTP using Klenow enzyme.
Northern blot hybridization analysis was performed essentially as described (5) . RNA was quantitated by PhosphorImager or by Scion Image (Scion Corp.).
Puri®cation of human RNase P from HeLa cells
RNase P from HeLa S3 cells or from stably transfected cell lines was puri®ed as previously described (7) . Brie¯y, 1±2 Q 10 9 cells were pelleted, disrupted and the whole cell extract was centrifuged at 20 000 g, followed by another centrifugation at 100 000 g to obtain S100 crude extract (7). (A) S100 crude extracts (100 mg) obtained from eight individual HeLa cell clones transfected with pCI-neo (clone C) or pCIRpp38H (clones 3±9) were subjected to western blot analysis using a monoclonal anti-polyhistidine antibody to test for Rpp38H expression. Proteins were separated by 12% SDS±PAGE, and positions of Rpp38H and protein size markers are indicated. (B) The membrane in (A) was analyzed using a monoclonal antibody against actin, 42 kDa, which serves as an internal control. (C) Schematic map of pCIRpp38H (not drawn to scale) containing a Rpp38 cDNA that has the 5¢-UTR and the entire coding region fused to six histidine (His) residues. The cDNA (Rpp38H) is subcloned in the multiple cloning site (MCS) of pCI-neo and transcribed from an upstream cytomegalovirus immediateearly promoter/enhancer (PCMV). Probe A (347 nt) and probe B (291 nt), used for RNase protection analysis, are shown. T3 indicates T3 RNA polymerase used to transcribe probe B.
Nucleic Acids Research, 2003, Vol. 31, No. 16 4837 This extract was loaded on a DEAE±Sepharose anion exchange chromatography column and the eluted fractions were tested for RNase P activity using the yeast suppressor precursor tRNA Ser (pSupS1) or Escherichia coli precursor tRNA Tyr as substrate. When crude extracts were assayed for RNase P, 5±20 U RNasin and 10 mg poly(I:C) were added to the reaction buffer to minimize precursor tRNA degradation. The speci®c activity of RNase P was determined as described (4) . Each assay of RNase P was repeated using crude cell extracts obtained from a series of similar transfection experiments.
Analysis of RNase P RNA and protein subunits
For protein analysis, western blotting was performed using monoclonal mouse antibody directed against polyhistidine tag (HIS-1), g-tubulin, actin (Sigma), C23 and B23 (Santa Cruz Biotechnology Inc.) or with af®nity-puri®ed polyclonal rabbit antibodies directed against Rpp subunits as described (5, 6) .
RNase P from crude extracts was immunoprecipitated with HIS-1 or polyclonal anti-Rpp antibodies and RNA in the immunoprecipitate was extracted with phenol:chloroform, precipitated by ethanol and then subjected to 3¢ end labeling with [ 32 P]cytidine phosphate or analyzed by northern blotting using antisense RNA probes transcribed from pBluescript(SK) harboring cDNAs of H1 RNA (340 nt) and MRP RNA (265 nt).
RESULTS
Selection of HeLa cells that constitutively express histidine-tagged Rpp38
HeLa S3 cells were transfected with pCIRpp38H, a eukaryotic expression vector that contains a gene that confers resistance to neomycin (G418) and a cDNA coding for a histidine-tagged Rpp38 protein (Rpp38H) (Fig. 1C) . G418-resistant cell foci obtained after 2±3 weeks were selected and established as separate cell lines (see Materials and Methods). After eight passages in tissue culture, S100 crude extracts were obtained from several selected cell lines and were subjected to western blot analysis using a monoclonal anti-polyhistidine antibody (HIS-1) to test for expression of Rpp38H. A protein of M r » 38 kDa that corresponds to Rpp38H was expressed in cell clones 3±6 (Fig. 1A, clones 3±6) but not in cells stably transfected with pCI-neo (Fig. 1A, clone C) . The level of Rpp38H expression was variable in these cell lines, the highest being in clones 5 and 6. Cell clones 7±9 were found to be resistant to G418, but expression of Rpp38H was not detectable (Fig. 1A, clones 7±9 ). This might be due to disruption of the Rpp38H cDNA as a result of random chromosomal DNA integration of pCIRpp38H.
Cell clones 3±6 exhibited slow growth rates (a 2-fold decrease in doubling time) when compared to those of cell clones 7±9 or to parental HeLa cells (data not shown). Furthermore, out of 15 individual cell clones that were selected for this study, only those that produced detectable levels of Rpp38H, including cell clones 3±6 described here, died after 11±14 passages in tissue culture. Therefore, high expression of Rpp38 is deleterious for survival of cells.
Lack of expression of endogenous Rpp38 in HeLa cells that produce Rpp38H
We next tested for expression of Rpp38H and Rpp38 mRNA in cell clones 3±9. To discriminate between these two mRNAs, which have similar sizes, total RNA extracted from clones 3±9 was subjected to quantitative RNase protection analysis using probe B. This 291 nt RNA probe covers the 3¢ end of the Rpp38 coding region (241 nt), the hexahistidine coding sequence, the stop codon and an extra 29 nt sequence spanning the multiple cloning site of the vector (map in Fig. 1C) . A 241 nt RNA was protected by Rpp38 mRNA in untransfected cells ( Fig. 2A , clone C1) and in cells transfected with pCI-neo ( Fig. 2A, clone C2 ). This mRNA, however, was barely detected in cell clones 3±6, which express Rpp38H protein ( Fig. 2A, clones 3±6 ). Instead, larger RNAs of 250± 260 nt that correspond to Rpp38H mRNAs were obtained ( Fig. 2A, clones 3±6 ). Since these Rpp38H mRNAs encoded intact protein products (Fig. 1A) , the 3¢ ends of the protected Rpp38H mRNAs differ by some nucleotides as a result of variations in the RNase protection assays. The triplet repeats enriched with AU (5¢-CAU CAU CAU CAU CAU CAU-3¢), which code for the C-terminal six histidine residues, may expose the probe annealed to the Rpp38H mRNAs to differential RNase A attacks. The use of probe A (map in Fig. 1C ) revealed the presence of intact 5¢-UTR sequences in Rpp38H mRNAs, an indication that there was no extensive elimination of these mRNA molecules in clones 3±6 (data not shown).
The lack of Rpp38 mRNA expression in cell clones 3±6 was accompanied by very low expression of endogenous Rpp38 protein (Fig. 2C , upper panel), but strikingly also of Rpp38H (Fig. 2C , upper panel). Because in this western blot analysis we used polyclonal rabbit antibodies raised against a histidinetagged recombinant Rpp38 (5), and therefore they presumably exhibit similar binding af®nities to Rpp38H and Rpp38, cell clones 3±6 seem to intrinsically produce low levels of Rpp38H, even though their Rpp38H mRNA levels were comparable to those of Rpp38 mRNA expressed in parental cells or in clones 7±9 (see Fig. 2A ). In fact, the variations in the levels of expression of Rpp38H in clones 3±6, as revealed by the HIS-1 antibody (Fig. 1A) , are below the normal levels of Rpp38 in control cells (Fig. 2C) . No change in Rpp30 levels has been observed in the various clones (Fig. 2C , lower panel).
Our ®ndings demonstrate that overproduction of Rpp38H in HeLa cells causes shut-off of the expression of endogenous Rpp38 at the mRNA level. The observation that Rpp38H mRNA can be detected ( Fig. 2A) while the Rpp38H protein level is low (Fig. 2C ) suggests a rapid degradation of the exogenous protein in the cell or weak translation of the Rpp38H mRNAs that lack authentic 3¢-UTR sequences.
Impaired activity of RNase P in extracts of cells expressing Rpp38H
The results described above raised the possibility that RNase P activity may also be affected in cell lines 3±6. Accordingly, S100 crude extracts described above were tested for enzyme function. A 2-to 3-fold reduction in the speci®c activity of RNase P, de®ned by the rate of substrate cleavage divided by total protein in the extract (4), in processing of precursor tRNA Ser was measured in clones 3±6 when compared to extracts of clones 7±9 or of control cells ( Fig. 2D and E) . The addition of a highly puri®ed recombinant Rpp38 protein, fused to a histidine tag (5) , to the extracts obtained from clones 7±9 and control cells, but not from clones 3±6, enhanced RNase P activity by 2-to 3-fold (Fig. 2E ). This enhancement is speci®c for recombinant Rpp38, because the addition of recombinant, histidine-tagged Rpp30 protein (5) did not stimulate enzyme activity in any extract tested (data not shown). Hence, recombinant, histidine-tagged Rpp38 is functional in terms of its ability to enhance RNase P activity (by binding and/or replacing Rpp38), but only in extracts from clones 7±9 and control cells. However, the reduced activity of the enzyme in clones 3±6 is not related to a reduction in total protein. This impaired activity is partly due to a reduction in the steady-state level of both Rpp38 and Rpp38H in cell clones 3±6 (Fig. 2C) . Additionally, RNase P produced in cells expressing low levels of Rpp38 may have defects in other subunits that cannot be alleviated by recombinant Rpp38 (see below).
Rpp38H is part of a defective RNase P complex S100 crude extracts from cell clone 6 described above were fractionated on a DEAE±Sepharose anion exchange chromatography column (7). Active RNase P was eluted from this column at 260±340 mM KCl (Fig. 3C, lanes 6 and 7) , a concentration of salt shown previously to elute RNase P ribonucleoprotein from untransfected HeLa S3 cells from the same column (4). Fractions F6 and F7 contained the peak of enzymatic activity (Fig. 3C ). Both Rpp38H (Fig. 3A) and Rpp30 (Fig. 3B) , as judged by western blot analysis using their corresponding antibodies described above, were found in F6 and F7. As with the S100 crude extracts ( Fig. 2D and E) , the activity of RNase P in fractions F6 and F7 was signi®cantly lower than that exhibited by DEAE-puri®ed RNase P obtained from untransfected HeLa cells (Fig. 3C, lane C) . Qualitative immunoprecipitation analysis using monoclonal antipolyhistidine antibody (HIS-1) revealed that Rpp38H was associated with active RNase P (data not shown) that has an H1 RNA smaller than 340 nt (Fig. 3D, lane 6, arrow) , the normal size of H1 RNA brought down by anti-Rpp38 antibody from untransfected HeLa cells (Fig. 3D, lane 7) . In contrast, the MRP RNA co-immunoprecipitated by HIS-1 or antiRpp38 antibodies was intact (265 nt) and no general degradation of other RNAs was seen (Fig. 3D, lane 6 versus 7) .
Reduced processing of tRNA in HeLa cells that express Rpp38H
To produce evidence that RNase P has impaired activity in Rpp38H-producing cells, the steady-state level of the initiator methionine tRNA in cell clones 3±6 was determined by northern blot hybridization analysis using an antisense RNA probe transcribed from the human tRNA i Met gene (see Materials and Methods). A 6-to 8-fold decrease in the level of the 75 nt tRNAi Met was measured in cell clones 4±6 (Fig. 4A, lanes 4±6) when compared to the level in untransfected HeLa cells (Fig. 4A, lane 1) or to cells transfected with vector alone (Fig. 4A, lane 2) . In contrast, only a 2-fold decrease in mature tRNA i Met was measured in clone 3 (Fig. 4A, lane 3) , which expressed lower levels of Rpp38H compared to clones 4±6 (Fig. 1A) . Moreover, a marked increase of 6-to 8-fold in the ratio of 5¢-tRNA i Met precursor containing the 5¢ leader sequence to mature tRNA i Met was pronounced in clones 5 and 6 when compared to the ratio obtained in control cells (Fig. 4A and E) . Accordingly, processing of precursor tRNA i
Met by RNase P is impaired in clones 3±6, which produce Rpp38H.
It has been shown that processing of tRNA i Met precursors is more sensitive than other tRNA precursors to RNase P inhibition in gcd14 yeast mutants (28) . The GCD14 gene codes for a protein essential for maturation of a subset of RNA polymerase III transcripts and cooperates with the La antigen (28) . Indeed, the reduction in the steady-state levels of another Figure 2 . Shut-off of Rpp38 mRNA and protein expression and impaired RNase P activity in cells expressing Rpp38H. (A) Total RNA extracted from untransfected HeLa cells (clone C1), cells transfected with pCI-neo (clone C2) and cell clones 3±9 (clones 3±9) was subjected to RNase protection analysis using uniformly labeled antisense probe B. Rpp38 mRNA protects 241 nt from the entire 291 nt probe, while Rpp38H mRNAs protect 250±270 nt. Since the probe has sequences derived from the plasmid and a 291 nt RNA was still seen in untransfected cells (clone C1), this RNA represents free probe. The shorter RNA bands indicated by asterisks represent Rpp38 mRNA species. The right-most lane represents undigested probe B (weaker exposure is presented). Numbers between panels indicate singlestranded DNA size markers generated by MspI digestion of pBlueScript. (B) Ethidium bromide staining of 18S and 28S rRNAs, used as internal controls for total RNA analyzed in (A). (C) S100 crude extracts from untransfected cells (clone C) and from cell clones 3±9 were subjected to western blot analysis using af®nity puri®ed antibodies against Rpp38 (upper panel) or Rpp30 (lower panel). (D) A representative assay of RNase P activity in S100 crude extracts with equal amounts of protein from clones 3±9 and from untransfected cells using precursor tRNA Ser as a substrate. Cleavage products were resolved in 8% polyacrylamide/7 M urea and mature tRNA (3¢) was quantitated as described in Materials and Methods. (E) Extracts were tested for RNase P activity in the absence (±rRpp38) or presence (+rRpp38) of 8 pmol of highly puri®ed recombinant Rpp38. This recombinant protein has a histidine tag at its N-terminus (5). The optical density values of tRNA are presented in arbitrary units.
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precursor tRNA, tRNA Ser , is less pronounced in these cells. When the same RNA blot in Figure 4A was rehybridized with an antisense RNA probe against human tRNA Ser only a 2-fold decrease in the level of this tRNA was seen in clones 5 and 6 (Fig. 4B) . Moreover, the ratio of precursor tRNA Ser to mature tRNA Ser was less pronounced when compared to that measured for tRNA i Met (Fig. 4A versus B) . Likewise, only a slight decrease in the steady-state level of tRNA Leu was observed in clones 3±6 (data not shown).
The above results indicate that tRNA processing is impaired in cells expressing Rpp38H, but processing of the initiator methionine tRNA precursor is particularly sensitive to the reduced activity of RNase P (see below).
Incorrect cleavage and reduced steady-state level of internal transcribed spacer 1 of rRNA in cells expressing Rpp38H
The yeast RNase MRP has been shown to cleave ITS1 rRNA at site A 3 , thus triggering the removal of the remaining downstream sequences by exoribonuclease activity to yield the 5¢-end of 5.8S S rRNA (29, 30 ). An RNase MRP-independent pathway produces the 5.8S L rRNA (29, 30) . A similar pathway for rRNA processing may exist in other eukaryotes (31) . Therefore, we checked for a defect in RNase MRP function by examining the steady-state level of 5.8S rRNA in cells expressing Rpp38H. We found no signi®cant change in the levels of 5.8S rRNAs in clones 3±6 when compared to those in control cells (Fig. 4C and F) . There was no alteration in the ratio of 5.8S S to 5.8S L rRNAs either (see below). Moreover, the steady-state level of mature 5S rRNA (121 nt) remained unaffected in these clonal cell populations ( Fig. 4D  and F) . However, quantitative RNase protection analysis of 3¢ ITS1 rRNA sequences in cells expressing Rpp38H revealed that their processing is actually not normal (Fig. 5A) . A 488 nt RNA that corresponds to positions 606±1094 of the 3¢ sequence of ITS1 rRNA was protected by the P2 probe when total RNA from cell clones 7±9 (Fig. 5A, lanes 7±9 ) and from control HeLa cells (Fig. 5A, lane 10) was ®rst analyzed. RNA of~320 nt in length, which was generated from endonucleolytic cleavage of ITS1 rRNA (32), was also protected in clones 7±9 and in control cells (Fig. 5A , lanes 7±9 and 10, respectively, arrow). This ®nding is consistent with previous S1 nuclease mapping analysis, in which it was shown that ITS1 rRNA is endonucleolytically cleaved in a U-tract region located 161±163 nt upstream of the 5.8S rRNA (33) . In addition, another minor RNA of~250 nt was also seen in these cells (Fig. 5A, lanes 7±10, arrow) . However, none of the three protected RNAs just described were detected when total RNA from clones 3±6 was analyzed (Fig. 5A, lanes 3±6) . Instead, rRNA fragments of 230±350 nt were obtained (Fig. 5A, lanes 3±6) .
The above analyses reveal that processing of 3¢ ITS1 rRNA is aberrant in clones 3±6, thereby implicating RNase MRP in rRNA processing in human cells. Work is in progress to Figure 3 . Rpp38H is associated with active RNase P that has truncated H1 RNA. (A) S100 crude extracts from cell clone 6 (Fig. 1A) were loaded on a DEAE±Sepharose chromatography column and all the eluted fractions obtained (lanes 1±10) were tested for the presence of Rpp38H as described in Figure  1A. (B) The membrane in (A) was analyzed for Rpp30 using af®nity puri®ed antibodies against Rpp30. Proteins were separated by 12% SDS±PAGE, and the positions of Rpp38H, Rpp30 and protein size markers are shown. The protein of M r » 72 kDa in (A) represents dimers of Rpp38H. (C) RNase P activity in the DEAE eluted fractions as determined by processing of precursor tRNA Tyr (S) to mature tRNA (3¢) and leader sequence (5¢). The right-most lane shows a control assay using a DEAE puri®ed RNase P from untransfected cells. The non-speci®c cleavage of precursor tRNA found in fractions that preceded RNase P activity is commonly seen during fractionation of S100 extracts on a DEAE column elucidate the enzymatic basis for processing of ITS1 rRNA by RNase MRP in vitro.
To verify whether the lack of 3¢ ITS1 rRNA sequences in clones 3±6 is the result of speci®c degradation, 5¢ sequences of ITS1 rRNA were quantitated through the use of the P1 probe that covers positions 31±598 of this spacer (Fig. 5C) . A 568 nt RNA was protected when total RNAs from cell clones 5 and 6 (Fig. 5B, lanes 3 and 4) and clones 7±9 (Fig. 5B, lanes 5±7) , as well as from control cells (Fig. 5B, lanes 1 and 2) , were analyzed. Moreover, analysis of the 3¢ end of ITS2 rRNA, using the P3 probe (Fig. 5C ) that covers positions 855±1112 of this downstream spacer, showed that this sequence existed in the cell clones expressing Rpp38H (Fig. 5D) . Accordingly, the absence of 3¢ ITS1 rRNA is due to enhanced degradation in cells that produce Rpp38H.
Inhibition of expression of Rpp38 by the use of small interfering RNA
We also examined the effect of inhibition of expression of endogenous Rpp38 on stable RNA processing in HeLa cells by the use of siRNA, designated siRNA38 (see Materials and Methods), which inhibited the expression of Rpp38 in a dosedependent manner as seen after transfection of cells for 24 (Fig. 6A, left panel) and 48 h (Fig. 6A, right panel) . A reduction of~50% in Rpp38 protein level was measured in cells transfected with 5.2 mg/ml of siRNA38, when compared to mock-treated cells and relative to g-tubulin, which served as an internal control (Fig. 6A, numbers below panels) . The ef®ciency of cell transfection, as determined by a reporter gene, pEGFP-C1, was 70±80% (data not shown). Cells treated with siRNA38 showed a slower growth rate (between 12 and 72 h after transfection), when compared to that of mocktreated cells (data not shown), but without affecting viability, as determined by FACS analysis (Fig. 6B) . No effect on Rpp38 expression was observed in the presence of siRNA directed against lamin A/C (data not shown).
Inhibition of Rpp38 expression by siRNA38 is not cell type speci®c, as destruction of Rpp38 by siRNA38 was also observed in 293 human embryonic kidney (HEK) cells (Fig. 6C, lane 1 versus 3) . A reduction of~66% in the Rpp38 level was measured in cells treated with 5.2 mg of siRNA38 (Fig. 6C) . The ef®ciency of cell transfection as determined by pEGFP-C1 was 70±90% (data not shown).
To obtain more information as to the targeting speci®city of the siRNA38 described above, we co-transfected HeLa cells with siRNA38 and pEGFP-Rpp38, an expression vector that contains the open reading frame of the Rpp38 cDNA fused to green¯uorescent protein (GFP) (25) . A signi®cant reduction of~90% in expression of GFP±Rpp38 has been measured in cells co-transfected with siRNA38, when compared to the control (Fig. 6D, lane 1 versus 2) . Similar results have been obtained with pEGFP-Rpp38D (Fig. 6D, lane 3 versus 4) , in which GFP was fused to Rpp38 lacking the last 36 amino acids that constitute a nucleolar localization domain (25) . Thereby, siRNA38 ef®ciently leads to the destruction of exogenous Rpp38 expressed in human cells. This discrepancy in the targeting ef®ciency of exogenous and endogenous Rpp38 by siRNA38 is not related to transfection ef®ciency. We are currently testing cell lines expressing siRNA38 and combinations of siRNAs directed against different regions in the Rpp38 mRNA.
The results described above show that siRNA38 speci®cally targets endogenous and exogenous Rpp38 for destruction in human cells.
Reduced activity of RNase P puri®ed from cells transfected with siRNA38
Whole crude extracts obtained from HeLa cells treated with various concentrations of siRNA38 were tested for RNase P activity using precursor tRNA Tyr (Fig. 7A) . A signi®cant reduction of~82% in tRNA processing has been measured in cells treated with 6.4 mg/ml siRNA38, when compared to control (Fig. 7B) . Expression of Rpp38 in these cells was inhibited by~84%, when compared to mock-treated cells (Fig. 7C, lane 1 versus 5) . A slight increase in the expression of the nucleolar phosphoprotein B23 (Fig. 7D ), but not of C23 (nucleolin) (Fig. 7E) , was observed in siRNA38-treated cells.
We also tested the expression of other protein subunits of human RNase P in siRNA38-treated cells and found no substantial changes in the levels of Rpp40, Rpp30 and Rpp14 (Fig. 7F, G and J, respectively) . In contrast, reductions of~54 and 73% in expression of the subunits Rpp21 and Rpp29 were measured ( Fig. 7I and H, respectively) .
RNase P immunoprecipitated from S20 protein extracts of siRNA38-treated cells by polyclonal antibodies against the subunit Rpp30 (5) showed an~50% reduction in processing of substrate (Fig. 7K, lane 3 versus 4) . This weak activity of RNase P, however, was not accompanied by any decrease in the steady-state level of H1 RNA, as judged by northern blot hybridization analysis of RNA precipitated with the antiRpp30 antibody (Fig. 7L, lane 3 versus 4) . Shorter H1 RNAs were seen both in control and siRNA38-treated cells (Fig. 7L,  lane 3 versus 4, asterisks) . The above observations reveal that the level of H1 RNA, MRP RNA and some protein subunits remained unchanged in cells that have an~80% reduction in the level of Rpp38, but some other subunits (Rpp21 and Rpp29) concomitantly decreased.
Processing of tRNA precursors in siRNA38-treated cells
To directly assess the effect of siRNA38 on RNase P activity in cells, total RNA was extracted from the siRNA38-treated cells and subjected to northern blot hybridization analysis using the antisense RNA probe derived from the gene encoding the initiator methionine tRNA (Fig. 8A) . Two precursors, 5¢-tRNA and 5¢-tRNA-3¢, accumulated in a dosedependent manner to increasing concentrations of siRNA38 ( Fig. 8A and B, lanes 2±5 ). 5¢-tRNA-3¢ represents the tRNA i
Met primary transcript that has a 5¢ leader sequence of 7 nt and 3¢ trailer of 2±4 nt in length (34) . The level of 5¢-tRNA increased by about 5-fold at 7.8 mg/ml siRNA38, when compared to the level in mock-treated cells (Fig. 8B, lane 5  versus 1, and C) . However, no concomitant decrease in the level of the mature tRNA i Met was detected ( Fig. 8A and B, lanes 2±5). No noticeable decrease in mature tRNA Tyr , tRNA Ser or tRNA Leu was observed (data not shown).
Kinetic analysis revealed that high levels of 5¢-tRNA i Met were observed after 20 h of cell transfection with 7.8 mg/ml siRNA38 and persisted for up to 50 h (Fig. 8D, lanes 2±5) . A concomitant, but slight, decrease in tRNA i Met was seen in these cells (Fig. 8D, lower panel) .
Processing of 5.8S rRNA in siRNA38-treated cells
We found no reduction in the levels of mature 5.8S rRNAs in siRNA38-treated cells, when compared to those in control cells (Fig. 8E and F, lanes 1 and 6 versus 2±5 ). The ratio of 5.8S S to 5.8S L rRNA remained unchanged (Fig. 8F) . However, two large rRNA transcripts have accumulated in the presence of siRNA38 (Fig. 8E, lanes 2±5, arrows) . The larger rRNA species accumulated at later time points during transfection (40±50 h) when compared to the smaller one (Fig. 8E , lanes 4 and 5). These transcripts may represent precursors containing 5.8S rRNA sequences but their accumulation did not alter the ®nal production of 5.8S rRNAs in response to inhibition of expression of Rpp38.
DISCUSSION
Role of Rpp38 in processing of tRNA precursors in human cells
We have shown that inhibition of expression of Rpp38 in human cells, whether by the use of the RNA interference approach or by constitutive expression of an exogenous, histidine-tagged Rpp38 protein, alters the activity of nuclear RNase P in tRNA processing. Processing of the initiator methionine tRNA precursor is particularly sensitive to inhibition of RNase P activity, when compared to processing of other tRNA precursors. Inhibition of expression of Rpp38 is accompanied by a decrease in the levels of some protein subunits, such as Rpp21 and Rpp29, but not of Rpp14, Rpp30, Rpp40 or H1 RNA. Therefore, the intracellular level of Rpp38 in¯uences the expression of certain protein subunits of RNase P and affects the processing of tRNA precursors.
Rpp38H expressed in cells is physically associated with RNase P that exhibits decreased speci®c activity, when compared to that of RNase P puri®ed from untransfected cells. This tagged ribonucleoprotein is assembled with a truncated H1 RNA that may affect its enzymatic activity. Additionally, the integration of Rpp38H into RNase P (Fig. 3 ) may change the overall structure or composition of the complex. Previous biochemical puri®cation analyses have indicated that the positively charged Rpp38 of human RNase P can be trapped on a cation exchange FPLC chromatography column, thus resulting in active, albeit unstable, holoenzyme that lacks this subunit (4,7). The addition of recombinant, histidine-tagged Rpp38 to this partially puri®ed holoenzyme can increase its activity. Moreover, Rpp38 is not required for substrate cleavage by RNase P in vitro (H. Mann and N. Jarrous, unpublished data). However, RNase P puri®ed from cells with reduced levels of Rpp38 exhibits very weak activity in processing of synthetic precursor tRNAs in vitro. Therefore, puri®ed complexes of nuclear RNase P do not necessarily re¯ect those in living cells in terms of catalysis or catalytic ef®ciency. Similar results have been reported for tRNA processing in HeLa cells in which Rpp38 was targeted by an external guide sequence (35) . In this latter study, a total reduction of 25% in tRNA levels has been reported (35) . Since other protein subunits were also inhibited along with Rpp38, the possibility exists that RNase P does not require all its subunits to ef®ciently process certain tRNA precursors in living cells. Alternatively, processing of tRNA in human cells can take place in the presence of trace amounts of intact RNase P. RNase P may utilize its distinct protein subunits to deal with the large number of tRNA isotypes expressed in growing cells. In support of these ®ndings, it has been shown that Pop3, the yeast homolog of Rpp38, can be depleted from Saccharomyces cerevisiae without abolishing RNase P activity and that this subunit is added at a late stage to a precursor RNase P ribonucleoprotein complex that is catalytically active (27) .
Function of Rpp38 in rRNA processing
In addition to the alteration in tRNA processing, defects in the cleavage and degradation of ITS1 rRNA are observed in HeLa cells that constitutively express Rpp38H. Although the enzymatic basis of processing of rRNA in human cells is not known in detail, our observations reveal that the 3¢ region of human ITS1 rRNA contains two endonucleolytic cleavage sites that have been affected by the constitutive production of Rpp38H. Because the 3¢ ITS1 rRNA in yeast serves as a substrate for RNase MRP (29) and the physical association of Pop3 (the homolog of Rpp38) with RNase MRP has been demonstrated by biochemical means (11), our results implicate human RNase MRP in processing of ITS1 rRNA. This non-essential role of RNase MRP in rRNA processing is further supported by the ®nding that precursor RNAs containing 5.8S rRNA sequences accumulated in siRNA38-treated cells. It remains to be shown if human RNase MRP can cleave model substrates of ITS1 rRNA.
One of the unexpected ®ndings of our study is the complete lack of 3¢ ITS1 rRNA sequences in cells expressing Rpp38H. Although processing of ITS1 rRNA is an early step in rRNA maturation and the half-life of rRNA intermediates with 3¢ ITS1 sequences is very short (29, 31) , the results indicate that these sequences, whether they exist as part of large rRNA transcripts or as free by-product molecules, are rapidly and ef®ciently eliminated in cells that produce Rpp38H. It has been shown that yeast 3¢ ITS1 rRNA sequences are degraded by exoribonucleases that functionally interact in synthetic lethal screens with RNase MRP (30, 36) . Since similar degradation events exist in higher eukaryotes (31, 37) , the lack of 3¢ ITS1 rRNA may involve excessive exonucleolytic activity in cells producing Rpp38H.
A role of Rpp38 in transcription?
The intracellular level of Rpp38, which is encoded by an intronless RPP38 gene candidate (2) is tightly regulated and selectively affects the expression of other RNase P protein subunits. The lack of normal expression of endogenous Rpp38 in HeLa cells that constitutively produce Rpp38H appears to involve a negative feedback mechanism that regulates RPP38 gene expression. Because the synthesis of both protein and mRNA for Rpp38 were inhibited in these cells, the molecular mechanism(s) responsible for this inhibition may act at the 
